STOCK TITAN

News for AXLA Stock

Axcella Announces Reverse Stock Split Effective September 19, 2023 Axcella Granted Patent for Long COVID Fatigue Treatment Axcella Reports Second Quarter Financial Results and Provides Business Update Axcella Reports First Quarter Financial Results and Provides Business Update Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023 Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue Axcella Announces Program Reprioritization and Corporate Restructuring Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting Axcella Reports Third Quarter Financial Results and Provides Business Update Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022 Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference Axcella Reports Second Quarter Financial Results and Provides Business Update Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference Axcella Reports First Quarter Financial Results and Provides Business Update Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022 Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference Axcella Therapeutics Announces Appointment of New Chief Financial Officer Axcella Therapeutics Details Clinical and Operational Milestones for 2022 Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021 Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021 Axcella Announces Upcoming Investor Conference Presentation Axcella Announces Upcoming Investor Conference Presentation Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH Axcella Reports Second Quarter Financial Results and Provides Business Update Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021 Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665 Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021 Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125 Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125 Axcella Reports First Quarter Financial Results and Provides Business Update Axcella to Report First Quarter 2021 Financial Results on May 6, 2021 Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021 Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021 Axcella Announces Alison D. Schecter, M.D., as President of R&D Axcella Announces Upcoming Presentations at NASH-TAG 2021 Axcella to Present at Upcoming Investor Conferences Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference Axcella Presents Data for AXA1125 at The Liver Meeting® 2020 Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update Axcella to Report Third Quarter 2020 Financial Results and Hold Conference Call on November 12, 2020 Axcella Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2020 New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs) Axcella Announces Upcoming Investor Conference Presentation
Back to Sitemap